CN115698045A - 肽标签和结合配偶体 - Google Patents

肽标签和结合配偶体 Download PDF

Info

Publication number
CN115698045A
CN115698045A CN202180038063.4A CN202180038063A CN115698045A CN 115698045 A CN115698045 A CN 115698045A CN 202180038063 A CN202180038063 A CN 202180038063A CN 115698045 A CN115698045 A CN 115698045A
Authority
CN
China
Prior art keywords
seq
tag
binding partner
peptide
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038063.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·E·富热鲁
A·F·S·贝特尔森
S·特拉内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adepovac Co ltd
Original Assignee
Adepovac Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adepovac Co ltd filed Critical Adepovac Co ltd
Publication of CN115698045A publication Critical patent/CN115698045A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202180038063.4A 2020-05-07 2021-05-07 肽标签和结合配偶体 Pending CN115698045A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
EP20173377.1 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
CN115698045A true CN115698045A (zh) 2023-02-03

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038063.4A Pending CN115698045A (zh) 2020-05-07 2021-05-07 肽标签和结合配偶体

Country Status (11)

Country Link
US (1) US20230321260A1 (enExample)
EP (1) EP4146675A1 (enExample)
JP (2) JP7843245B2 (enExample)
KR (1) KR20230006473A (enExample)
CN (1) CN115698045A (enExample)
AU (1) AU2021268757B2 (enExample)
BR (1) BR112022019632A2 (enExample)
CA (1) CA3177709A1 (enExample)
IL (1) IL297111A (enExample)
MX (1) MX2022013938A (enExample)
WO (1) WO2021224451A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
CN117723749A (zh) * 2024-02-07 2024-03-19 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026119880A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit thymic stromal lymphopoietin
WO2026119878A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit native interleukin-11 signaling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130053544A1 (en) * 2010-02-11 2013-02-28 Isis Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CN107406514A (zh) * 2014-11-03 2017-11-28 默克专利有限公司 可溶内含肽融合蛋白以及用于纯化生物分子的方法
CN110177811A (zh) * 2016-11-16 2019-08-27 奥克兰联合服务有限公司 用于蛋白质连接的方法及其用途
CN111073925A (zh) * 2018-10-19 2020-04-28 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130053544A1 (en) * 2010-02-11 2013-02-28 Isis Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CN107406514A (zh) * 2014-11-03 2017-11-28 默克专利有限公司 可溶内含肽融合蛋白以及用于纯化生物分子的方法
CN110177811A (zh) * 2016-11-16 2019-08-27 奥克兰联合服务有限公司 用于蛋白质连接的方法及其用途
CN111073925A (zh) * 2018-10-19 2020-04-28 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
CN117723749A (zh) * 2024-02-07 2024-03-19 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Also Published As

Publication number Publication date
EP4146675A1 (en) 2023-03-15
KR20230006473A (ko) 2023-01-10
AU2021268757A1 (en) 2022-12-08
BR112022019632A2 (pt) 2023-10-03
AU2021268757B2 (en) 2026-07-09
CA3177709A1 (en) 2021-11-11
MX2022013938A (es) 2022-11-30
JP2026048917A (ja) 2026-03-17
WO2021224451A1 (en) 2021-11-11
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
IL297111A (en) 2022-12-01
US20230321260A1 (en) 2023-10-12
WO2021224451A9 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7843245B2 (ja) ペプチドタグおよび結合パートナー
CA2583009C (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
US10197562B2 (en) Multiplex immuno screening assay
JP5651476B2 (ja) 所定のスカフォールドを有するポリペプチドライブラリー
CN1561394A (zh) 人嗜中性粒细胞明胶酶相关脂卡林及有关蛋白的突变蛋白
CN116199733A (zh) 融合蛋白合成的方法和产品
CN107427571A (zh) 基于纳米颗粒的新型多价疫苗
HUE029919T2 (en) Genetically modified antibody stress protein fusions
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
CN116621947B (zh) 一种基于索烃骨架的拓扑蛋白质、制备方法及应用
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
CN116444623B (zh) 一种基于纳米颗粒支架的纳米疫苗及其制备方法与应用
CN118440213A (zh) 一种提高多结构域纳米颗粒产量的方法
US9914757B2 (en) Methionyl tRNA synthetase for biosynthesis of photomethionine-labeled protein and method for preparing photoactive protein G variant using same
CN120025428B (zh) 一种靶向NS3a的纳米抗体及其应用
CN114539412B (zh) 抗hla-a2/wt1复合物的单域抗体及其制备方法与应用
CN114716563B (zh) 一种融合蛋白及其制备与应用
CN114349859B (zh) 抗EGFRvⅢ的纳米抗体EGFRvⅢ/Nb1-11及其制备方法与应用
CN120283055A (zh) 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法
CN122038361A (zh) 一种高亲和力的肉毒杆菌神经毒素a受体结合结构域突变体及其应用
WO2024238632A2 (en) Asymmetric circular tandem repeat proteins
CN120136979A (zh) 一种靶向结合PCNA蛋白的binder、融合蛋白及其应用
JP2023057069A5 (enExample)
WO2026037258A1 (zh) 具有改善的热稳定性的分选酶
CN116348479A (zh) 用于产生丝状噬菌体的细菌菌毛蛋白质复合物FimGt-DsF稳定蛋白质复合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination